Sava Infond D.O.O. Alnylam Pharmaceuticals, Inc. Transaction History
Sava Infond D.O.O.
- $643 Million
- Q3 2025
A detailed history of Sava Infond D.O.O. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Sava Infond D.O.O. holds 1,640 shares of ALNY stock, worth $741,198. This represents 0.12% of its overall portfolio holdings.
Number of Shares
1,640
Previous 2,180
24.77%
Holding current value
$741,198
Previous $711 Million
99.89%
% of portfolio
0.12%
Previous 0.11%
Shares
4 transactions
Others Institutions Holding ALNY
# of Institutions
852Shares Held
117MCall Options Held
608KPut Options Held
678K-
Capital World Investors Los Angeles, CA16.8MShares$7.6 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.13 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.32 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.25 Billion0.49% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.05 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...